An unsolicited (hostile) bid is, I guess, conceivable -- I wondered about that earlier this week -- but hard to imagine, and would be extremely counterproductive for Pfizer if they really wanted to acquire AMRN.
If you want to get this thing at a somewhat discounted price you need it to be a friendly deal. You don't want to start a bidding war with an aggressive, lowball bid.
News 
Market Data 
Discover 
